Treatment and Prevention of Cytomegalovirus Infections
Treatment of systemic virus diseases is still largely experimental, although rapid progress is being made. The basic problem has been that putative antiviral agents may not be effective enough or are too toxic. Evaluation of the effect of these drugs may also be difficult. Frequently, the disease that is treated has a variable course, and the demonstration of efficacy of an antiviral may not be possible except by a blind, controlled study in which the drug-treated group is compared to a placebotreated group. Such studies are expensive to undertake, and although the knowledge gained is usually solid, it is often limited. On the other hand, when a drug seems to be effective, controlled studies are also difficult to undertake.
KeywordsRenal Transplant Recipient Vaccine Strain Transfer Factor Immune Globulin Seropositive Donor
Unable to display preview. Download preview PDF.